Skip to main content
. 2020 Jun 1;9(5):56. doi: 10.1038/s41389-020-0239-7

Fig. 6. MeCP2 facilitates breast cancer growth by regulating RPL11/RPL5-P53 pathway in vivo.

Fig. 6

a Small animal imaging of tumor-bearing mice (up) and gross morphology of xenograft (bottom) 40 days after injection. b Tumor weight at day 40 after injection. c Growth curves of tumor. Tumor volume was generated every 5 days for 40 days. *P < 0.05, **P < 0.01. d qRT-PCR of MeCP2, RPL11 and RPL5 expressions in tumor xenografts. e IHC staining of MeCP2 and P53 in xenografts. f The protein levels of Bcl2, P53, BAX, P21, RPL11, and RPL5 in vivo. g Proposed model for the effect of MeCP2 on breast cancer growth. MeCP2 facilitated breast cancer cell proliferation by binding to RPL11 or RPL5 promoter region and suppressing their expressions, thereby promoting ubiquitination-mediated P53 degradation.